Tag

Gufic Biosciences Limited

5 articles
Gufic Biosciences is demonstrating robust financial performance and strategic expansion, highlighted by a 58% year-over-year increase in profit after tax for the second quarter of fiscal year 2027. The company's revenue grew by 25% year-over-year, driven by international business growth with new registrations and orders in key markets like Saudi Arabia and Azerbaijan. Furthermore, Gufic is advancing its regulated market entry plans with successful US FDA pre-approval inspections at its Indore facility and anticipates EU GMP certification, alongside strengthening its board with the appointment of Dr. Reeta Shah as an independent director. An ESG rating of 69.7/100 further underscores the company's commitment to sustainability, positioning Gufic for continued growth and investor interest.